Browse studies
Find your next paid study
16 recruiting studies matching your filters
Phase 1
Phase 1A/1B Trial of BTM-3566 in Relapsed/Refractory Mature B Cell Lymphomas
The goal of this clinical trial is to learn if BMT-3566 can safety be given to adult patients with relapsed or refractory mature b cell lymphomas. It will also…
Lymphoma, B-Cell
Estimated
~$10 – $8,750
Bantam PharmaceuticalsNCT06792734
Phase 1
LMY-920 for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
Therapy with chimeric antigen receptor T (CAR-T) cells has demonstrated activity against refractory lymphoma, however not all tumors respond or remain in respo…
Lymphoma, Non-Hodgkin Lymphoma, B-Cell
Estimated
~$10 – $8,750
Luminary TherapeuticsNCT05312801
Phase 2
TPG: a Phase 2 Trial of Polatuzumab Vedotin, Glofitamab, and Tafasitamab as Chemotherapy-sparing First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
This is a single-center, phase 2, open-label clinical trial of a novel combination of polatuzumab vedotin, glofitamab, and tafasitamab (TPG) as first-line trea…
Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaLymphoma+1 more
Estimated
~$10 – $6,250
Brown UniversityNCT07502872
Phase 1
A Phase I Study of Tagraxofusp With or Without Chemotherapy in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Tagraxofusp is a protein-drug conjugate consisting of a diphtheria toxin redirected to target CD123 has been approved for treatment in pediatric and adult pati…
Hematologic MalignancyAMLALL+8 more
Estimated
~$10 – $7,500
Therapeutic Advances in Childhood Leukemia ConsortiumNCT05476770